Navigation Links
NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million
Date:10/28/2010

The Georgia Tech-led Nanomedicine Center for Nucleoprotein Machines has received an award of $16.1 million for five years as part of its renewal by the National Institutes of Health (NIH). The eight-institution research team plans to pursue development of a clinically viable gene correction technology for single-gene disorders and demonstrate the technology's efficacy with sickle cell disease.

Sickle cell disease is a genetic condition present at birth that affects more than 70,000 Americans. It involves a single altered gene that produces abnormal hemoglobin the protein that carries oxygen in the blood. In sickle cell disease, red blood cells become hard, sticky and "C" shaped. Sickle cells die early, which causes a constant shortage of red blood cells. The abnormal cells also clog the flow in small blood vessels, causing chronic pain and other serious problems such as infections and acute chest syndrome.

"Even though researchers know sickle cell disease is caused by a single A to T mutation in the beta-globin gene, there is no widely available cure," said center director Gang Bao, the Robert A. Milton Chair in Biomedical Engineering in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. "By directly and precisely fixing the single mutation, we hope to reduce or eliminate the sickle cell population in an individual's blood stream and replace the sickle cells with healthy red blood cells."

The center is one of eight NIH Nanomedicine Development Centers established in 2005 and 2006, a key initiative of the NIH's long-term nanomedicine research goals. The centers have highly multidisciplinary scientific teams that include biologists, physicians, mathematicians, engineers and computer scientists. Through an intense competition, the NIH selected four centers for second phase funding, including the one led by Georgia Tech.

In addition to experts in the Coulter Department of Biom
'/>"/>

Contact: Abby Vogel Robinson
abby@innovate.gatech.edu
404-385-3364
Georgia Institute of Technology Research News
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. NY Gov. Paterson renews commitment to stem cell research in visit to Cold Spring Harbor Laboratory
2. HHMI renews grant for Rices global health program
3. UT nanomedicine project to be tested in space
4. All-in-1 nanoparticle: A Swiss Army knife for nanomedicine
5. Toward a nanomedicine for brain cancer
6. Findings show nanomedicine promising for treating spinal cord injuries
7. Nanomedicine: Ending hit and miss design
8. NSF funds new Center for the Physics of Living Cells at Illinois
9. Rice University establishes National Corrosion Center
10. New center will focus environmental debate and produce solutions for action
11. Research center to free chemistry from Earths bonds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/11/2017)... Johnson, co-founder of Visikol Inc. a company originally funded with an ... the elite "Forbes 30 Under 30" list in the Science category. ... fields nationwide to be recognized as a leader in business and ... ... PhD candidate at Rutgers University. Visikol , ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... and scientists from around the world, was today awarded the "Best Science & ... based entirely on merit and decided upon by a dedicated team of researchers ...
(Date:1/19/2017)... Md. , Jan. 18, 2017  Northwest Biotherapeutics, ... developing DCVax® personalized immune therapies for operable and inoperable ... Bosch , Chief Technical Officer of NW Bio, will ... January 19, 2017, at the Hyatt Regency Hotel in ... Bosch will chair the session entitled "New Therapeutic Approaches ...
(Date:1/18/2017)... -- According to a new market research report "In situ Hybridization ... End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to ... by 2021 from USD 557.1 Million in 2016, growing at a CAGR of ... ... MarketsandMarkets Logo ...
Breaking Biology Technology: